# Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

> **NCT01828008** · — · UNKNOWN · sponsor: **Han weidong** · enrollment: 20 (estimated)

## Conditions studied

- Lymphomas

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01828008
- **Lead sponsor:** Han weidong
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2013-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01828008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01828008, "Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01828008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*